A phase 2 randomized, placebo-controlled study on the efficacy and safety of AR1001, a phosphodiesterase-5 inhibitor, in patients with mild-to-moderate Alzheimer's disease.

J Prev Alzheimers Dis · 2025 · PMC12501329 · PMID 40912996

Europe PMC DOI

hedged sentence

0.0520

closest p · 1.0× alpha

0.0520

boldest claim

The sentences

did not reach statistical significancep = .052so close (0.05 < p ≤ 0.1)

Although the difference in NfL did not reach statistical significance (p = .052), the direction of effect favored AR1001.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.